TrialJAMA neurology2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
Bruce A C Cree et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papertrialcites it
TrialJAMA neurology2026
Bruce A C Cree et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.